Filtered By:
Drug: SGLT2 Inhibitors

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 230 results found since Jan 2013.

Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis
Conclusions: Compared with placebo, SGLT2 inhibitors conclusively reduce the risk of MACE, CVD or HHF, ACD, CVD, HHF, and KFP in patients with type 2 diabetes, whereas the effects of SGLT2 inhibitors on MI and stroke are not conclusive and need to be further assessed in future studies with the adequate sample size to reject or accept the effect size.
Source: Medicine - March 12, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Use of sodium –glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
ConclusionIn a contemporary HF cohort with T2DM, SGLT2i use increased over time, was more common with specialist care, younger age, ischaemic heart disease, and preserved renal function, and was associated with lower mortality and morbidity.
Source: European Journal of Heart Failure - March 3, 2021 Category: Cardiology Authors: Peter M. Becher, Benedikt Schrage, Giulia Ferrannini, Lina Benson, Javed Butler, Juan Jesus Carrero, Francesco Cosentino, Ulf Dahlstr öm, Linda Mellbin, Giuseppe M.C. Rosano, Gianfranco Sinagra, Davide Stolfo, Lars H. Lund, Gianluigi Savares Tags: Research Article Source Type: research

Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy.
Conclusions: Risk of residual confounding cannot be fully excluded. Individual therapeutic agents within each class may have different magnitudes of effect. In this large real-world cohort of diabetic patients already on GLP-1RA, addition of SGLT2i - compared to addition of sulfonylurea - conferred greater cardiovascular benefit. The magnitude of the cardiovascular risk reduction was comparable to the benefit seen in cardiovascular outcome trials of SGLT2i versus placebo where baseline GLP-1RA use was minimal. PMID: 33302723 [PubMed - as supplied by publisher]
Source: Circulation - December 11, 2020 Category: Cardiology Authors: Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E Tags: Circulation Source Type: research

Sodium-glucose transport protein 2 inhibitors and risk of incident stroke: A systematic review and meta-analysis
Background and Aims: Although experimental studies have suggested a potential neuroprotective effect of sodium-glucose contransporter-2 (SGLT2) inhibitors, human trials have demonstrated controversial results regarding their effect on the risk of stroke. In this context, we evaluated published evidence regarding the effect of treatment with SGLT2 inhibitors on the risk of ischemic stroke.
Source: Atherosclerosis - December 1, 2020 Category: Cardiology Authors: F. Barkas, E. Liberopoulos, S. Filippas Ntekouan, H. Milionis Source Type: research

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Conclusion: SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-...
Source: International Journal of Nephrology and Renovascular Disease - November 7, 2020 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
Conclusion: SGLT2 inhibitors can be a good second-line drug to reduce the incidence of cardiovascular diseases compared with DPP-4 inhibitors or sulfonylureas in people with type 2 diabetes mellitus. PMID: 33120439 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism Journal - October 31, 2020 Category: Endocrinology Tags: Diabetes Metab J Source Type: research

Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
CONCLUSIONS: It is unlikely that SGLT inhibitors have a positive or negative effect on stroke risk, but the question that remains unanswered is whether SGLT inhibitors can yield a protective effect after acute ischemic stroke. Future observational studies and registries may be the first step to help answer this question. (Clin Ther. 2020; XX:XXX-XXX) © 2020 Elsevier HS Journals, Inc. PMID: 33008610 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - September 28, 2020 Category: Drugs & Pharmacology Authors: Al Hamed FA, Elewa H Tags: Clin Ther Source Type: research

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.
lar Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health Abstract Chronic kidney disease (CKD) with type 2 diabetes (T2D) is a major public health problem, resulting in significant cardiovascular and kidney adverse outcomes worldwide. Despite the widespread use of standard-of-care therapies for CKD with T2D over the past few decades, rates of progression to end-stage kidney disease remain high with no beneficial impact on its accompanying burden of cardiovascular disease. The advent of the newer classes of antihyperglycemic agent...
Source: Circulation - September 27, 2020 Category: Cardiology Authors: Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, Lo KB, Tuttle K, Vaduganathan M, Ventura H, McCullough PA, American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vasc Tags: Circulation Source Type: research

Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients 　- A Randomized Controlled Trial.
CONCLUSIONS: Dapagliflozin significantly improved RVSP and LVFP during exercise in patients with T2DM and cardiovascular risk, which may contribute to favorable effects on heart failure. PMID: 32921680 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 11, 2020 Category: Cardiology Authors: Kayano H, Koba S, Hirano T, Matsui T, Fukuoka H, Tsuijita H, Tsukamoto S, Hayashi T, Toshida T, Watanabe N, Hamazaki Y, Geshi E, Murakami M, Aihara K, Kaneko K, Yamada H, Kobayashi Y, Shinke T Tags: Circ J Source Type: research

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes
Conclusion: Dapagliflozin seemingly influences systemic and renal hemodynamics independently and beyond glucose lowering in people with type 2 diabetes. This clinical trial was registered at https://clinicalTrials.gov (ID: NCT02682563).
Source: Journal of Hypertension - August 13, 2020 Category: Cardiology Tags: ORIGINAL PAPERS: Treatment Source Type: research

SGLT2 inhibitors compared with other glucose ‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
In conclusion, SGLT2i initiators had lower risks of CV events versus oGLD initiators and, uniquely, versus DPP4i initiators in Japanese real‐world practice.
Source: Journal of Diabetes Investigation - June 11, 2020 Category: Endocrinology Authors: Shun Kohsaka, Masayoshi Takeda, Johan Bodegard, Marcus Thuresson, Mikhail Kosiborod, Toshitaka Yajima, Eric Wittbrodt, Peter Fenici Tags: SHORT REPORT Source Type: research

Comment on "Subtype-Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study".
PMID: 32408385 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Pharmacology - May 13, 2020 Category: Drugs & Pharmacology Authors: Cure E, Cumhur Cure M Tags: J Clin Pharmacol Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
Large cardiovascular outcome trials (CVOTs) have lent support to a cardiovascular protection with the use of SGLT2-inhibitors (SGLT2is) and GLP1-Receptor Agonists (GLP1-RAs) in subjects with type 2 diabetes. These two classes of novel glucose lowering agents have been shown to have a similar effect on the risk reduction of Major Adverse Cardiovascular Events (MACE: nonfatal myocardial infarction, nonfatal stroke, cardiovascular mortality). Nonetheless, they may not be simply interchangeable. Rather, careful evaluation of all the results of CVOTs allows identification of different effects that may allow profiling of the ide...
Source: Diabetes Research and Clinical Practice - March 16, 2020 Category: Endocrinology Authors: Angela Dardano, Roberto Miccoli, Cristina Bianchi, Giuseppe Daniele, Stefano Del Prato Source Type: research